Mechanistically, TRIM25 inhibits oxidative stress and ferroptotic cell death during TMZ treatment by promoting the nuclear import of Nrf2 through Keap1 ubiquitination, highlighting its role in glioblastoma chemoresistance and its promise as a therapeutic target [70]. Here, TRIM25 is linked to glioblastoma.